Curocell
Financials
Valuation Metrics
Curocell's Market Cap is ₩3274B. At end of 2025 it was ₩6845B. Ranked #621 of 2,421 in KR market (top 26%), #256 of 1,640 on KOSDAQ (top 16%), #64 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 327.38B KRW | KR#621/2,421 Sec#64/231 |
| Revenue | 0 KRW | KR#2,396/2,421 Sec#227/231 |
| Net Income | -54.08B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 164.61B KRW | KR#1,439/2,421 Sec#110/231 |
| Net Assets | 72.52B KRW | KR#1,651/2,421 Sec#137/231 |
| Employees | 126 | KR#1,462/2,421 Sec#116/231 |
| Value | ||
| P/B | 4.51x | KR#2,218/2,421 Sec#187/231 |
| FCF Yield | -9.26% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -74.57% | KR#2,327/2,421 Sec#212/231 |
| ROA | -32.85% | KR#2,329/2,421 Sec#204/231 |
| Financial Health | ||
| Debt Ratio | 126.98% | KR#1,766/2,421 Sec#197/231 |
| Total Debt | 58.67B KRW | KR#940/2,421 Sec#62/231 |
| FCF | -30.31B KRW | KR#1,992/2,421 Sec#192/231 |
| Cash | 17.15B KRW | KR#1,339/2,421 Sec#104/231 |
| Current Ratio | 1.82x | KR#966/2,421 Sec#107/231 |
| Performance | ||
| 1Y Return | -49.29% | KR#2,047/2,421 Sec#186/231 |
| 1M Return | -12.96% | KR#2,196/2,421 Sec#183/231 |
| From 52W High | -67.42% | KR#2,130/2,421 Sec#176/231 |
| 1Y MDD | -67.92% | KR#1,891/2,421 Sec#161/231 |
| Trading | ||
| Volume | 15,902 shares | KR#1,702/2,421 Sec#167/231 |
| Trading Value | 339.9M KRW | KR#1,083/2,421 Sec#111/231 |
| Foreign Own. | 1.63% | KR#1,780/2,421 Sec#173/231 |
| Per Share | ||
| EPS | -3,552 KRW | KR—/2,421 Sec—/231 |
| BPS | 4,763 KRW | KR#1,534/2,421 Sec#110/231 |
Company Info
Qurocell was established in 2016 as a specialized enterprise for CAR-T therapeutic agent development and listed on the KOSDAQ market in 2023. The company holds several new drug pipelines, including CD19 CAR-T therapeutic agents, and completed clinical trials for Limcato, which applies OVIS™ CAR-T technology. Aiming for a 2025 product launch, it completed a manufacturing facility and applied for product approval in 2024, while also exploring expanded development for various cancer types and overseas market entry. Qurocell is headquartered in Yuseong-gu, Daejeon Metropolitan City.